{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:31:52Z","timestamp":1787905912019,"version":"build-2784847793"},"reference-count":46,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Multidrug-resistant tuberculosis (MDR-TB) remains a global public health challenge, complicating treatment strategies and requiring advanced therapeutic approaches. The persistence of MDR-TB has led to a demand for regimens that are more effective in improving treatment outcomes and controlling transmission. This systematic review and meta-analysis sought to examine the efficacy of linezolid (LZD) and bedaquiline (BDQ) in MDR-TB treatment regimens, evaluating their roles in enhancing therapeutic success and informing optimized management of MDR-TB. Methods: A comprehensive search was conducted across MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science for randomized controlled trials assessing the efficacy of LZD and BDQ in MDR-TB patients up to September 14, 2024. We analyzed treatment outcomes, reporting favorable outcomes (cured and treatment completed) and unfavorable outcomes (death, treatment failure, and loss to follow-up) with a 95% confidence interval. Results: Our analysis included 11 trials, with a total of 1,999 participants. The findings indicate that BDQ+LZD-containing regimens yield significantly higher favorable treatment outcomes (84.5%; 95% CI, 79.8%-88.2%) and lower unfavorable outcomes (15.4%; 95% CI, 11.6%-20.2%). In contrast, regimens lacking either LZD or BDQ show lower efficacy, with favorable outcomes at 66.8% (95% CI, 59.5%-73.4%) and unfavorable outcomes at 33.0% (95% CI, 25.6%-41.4%). Conclusions: MDR-TB treatment regimens including BDQ and LZD lead to significantly better patient outcomes. The combined bactericidal and protein synthesis-inhibiting effects of BDQ and LZD create a powerful therapeutic synergy. Adding pretomanid further enhances this effectiveness, highlighting its value in complex cases. Future research should focus on optimizing these regimens for safety and efficacy and explore adjunctive therapies to improve MDR-TB outcomes even further.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240391","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:46:12Z","timestamp":1738788372000},"page":"e20240391","source":"Crossref","is-referenced-by-count":6,"title":["Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis"],"prefix":"10.36416","author":[{"given":"Mahdis","family":"Cheraghi1","sequence":"first","affiliation":[{"name":"1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Amiri1","sequence":"additional","affiliation":[{"name":"1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Andarzgoo2","sequence":"additional","affiliation":[{"name":"2. Faculty of Nursing and Midwifery, Islamic Azad University, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zarei3","sequence":"additional","affiliation":[{"name":"3. School of Medicine, Bam University of Medical Sciences, Bam, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sadat Seghatoleslami4","sequence":"additional","affiliation":[{"name":"4. Department of Infectious Diseases, Islamic Azad University, Tehran Medical Branch, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis5","sequence":"additional","affiliation":[{"name":"5. Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"D\u2019Ambrosio6","sequence":"additional","affiliation":[{"name":"6. Public Health Consulting Group, Lugano, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Pontali7","sequence":"additional","affiliation":[{"name":"7. Servizio di Malattie Infettive, Hospital Galliera, Genova, Italia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Javad Nasiri1","sequence":"additional","affiliation":[{"name":"1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Battista Migliori5","sequence":"additional","affiliation":[{"name":"5. Istituti Clinici Scientifici Maugeri - IRCCS - Tradate, Italia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Migliori GB, Sotgiu G, D\u2019Arcy Richardson M, Centis R, Facchini A, Guenther G, et al. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J. 2009;34(3):778-779. https:\/\/doi.org\/10.1183\/09031936.00059409","DOI":"10.1183\/09031936.00059409"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.           Motta I, Boeree M, Chesov D, Dheda K, G\u00fcnther G, Horsburgh CR Jr, et al. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2024;30(9):1107-1114. https:\/\/doi.org\/10.1016\/j.cmi.2023.07.013","DOI":"10.1016\/j.cmi.2023.07.013"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Wei X, Yue L, Zhao B, Jiang N, Lei H, Zhai X. Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment. Eur J Med Chem. 2024;277:116785. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116785","DOI":"10.1016\/j.ejmech.2024.116785"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           World Health Organization (WHO) [homepage on the Internet]. Geneva: WHO; c2024 [updated 2024 Aug 19; cited 2024 Nov 1]. Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/B09123","DOI":"10.2471\/b09123"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Saderi L, Cabibbe AM, Puci M, Di Lorenzo B, Centis R, Pontali E, et al. A systematic review of the costs of diagnosis for multidrug-resistant\/extensively drug-resistant TB in different settings. Int J Tuberc Lung Dis. 2023;27(5):348-356. https:\/\/doi.org\/10.5588\/ijtld.22.0657","DOI":"10.5588\/ijtld.22.0657"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           Pontali E, Raviglione M. Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?. IJTLD Open. 2024;1(11):486-489. https:\/\/doi.org\/10.5588\/ijtldopen.24.0490","DOI":"10.5588\/ijtldopen.24.0490"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           World Health Organization (WHO) [homepage on the Internet]. Geneva: WHO; c2024 [updated 2024 Oct 29; cited 2024 Nov 1]. Global Tuberculosis Report 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024","DOI":"10.1371\/journal.pgph.0003655"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45(1):25-29. https:\/\/doi.org\/10.1183\/09031936.00145014","DOI":"10.1183\/09031936.00145014"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.           Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D\u2019Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. https:\/\/doi.org\/10.1183\/13993003.00387-2017","DOI":"10.1183\/13993003.00387-2017"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.        Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J, 2019. 54(6).","DOI":"10.1183\/13993003.01522-2019"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Pontali E, Sotgiu G, Tiberi S, D\u2019Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5):1701462. https:\/\/doi.org\/10.1183\/13993003.01462-2017","DOI":"10.1183\/13993003.01462-2017"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.        Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021;27(5):403-412. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.02.006","DOI":"10.1016\/j.pulmoe.2021.02.006"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Borisov SE, D\u2019Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. J Infect. 2019;78(1):35-39. https:\/\/doi.org\/10.1016\/j.jinf.2018.08.003","DOI":"10.1016\/j.jinf.2018.08.003"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D\u2019Ambrosio L, et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018;52(1):1800934. https:\/\/doi.org\/10.1183\/13993003.00934-2018","DOI":"10.1183\/13993003.00934-2018"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Sotgiu G, Centis R, D\u2019Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430-42. https:\/\/doi.org\/10.1183\/09031936.00022912","DOI":"10.1183\/09031936.00022912"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Oehadian A, Bastos ML, Centis R, D\u2019Ambrosio L, Migliori GB, Santoso P, et al. Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB. Pulmonology. 2024;30(2):184-187. https:\/\/doi.org\/10.1016\/j.pulmoe.2023.09.003","DOI":"10.1016\/j.pulmoe.2023.09.003"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, et al. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. Clin Infect Dis. 2018;67(suppl_3):S327-S335. https:\/\/doi.org\/10.1093\/cid\/ciy625","DOI":"10.1093\/cid\/ciy625"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20132017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-834. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1","DOI":"10.3410\/f.733954037.793565561"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        World Health Organization (WHO) [homepage on the Internet]. Geneva: WHO; c2023 [cited 2024 Nov 1].Global tuberculosis report 2023. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023","DOI":"10.1371\/journal.pgph.0003655"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384. https:\/\/doi.org\/10.36416\/1806-3756\/e20210384","DOI":"10.36416\/1806-3756\/e20210384"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.        Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403-412. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.02.006","DOI":"10.1016\/j.pulmoe.2021.02.006"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.        Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis. 2022;76(3):e938-46. https:\/\/doi.org\/10.1093\/cid\/ciac528","DOI":"10.1093\/cid\/ciac528"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384. https:\/\/doi.org\/10.36416\/1806-3756\/e20210384","DOI":"10.36416\/1806-3756\/e20210384"},{"key":"ref23","unstructured":"24.        World Health Organization, Guidelines for surveillance of drug resistance in tuberculosis, 4th ed. Geneva: World Health Organization; 2009."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.        Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522. https:\/\/doi.org\/10.1183\/13993003.01522-2019","DOI":"10.1183\/13993003.01522-2019"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Viney K, Linh NN, Gegia M, Zignol M, Glaziou P, Ismail N, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J. 2021;57(4):2100361. https:\/\/doi.org\/10.1183\/13993003.congress-2021.OA1599","DOI":"10.1183\/13993003.00361-2021"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.        Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20132017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-834. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1","DOI":"10.3410\/f.733954037.793565561"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022.","DOI":"10.37774\/9789275327869"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.        Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.        Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810-823. https:\/\/doi.org\/10.1056\/NEJMoa2119430","DOI":"10.1056\/nejmoa2119430"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.        Guglielmetti L, Tiberi S, Burman M, Kunst H, Wejse C, Togonidze T, et al. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. Eur Respir J. 2018;52(2):1800537. https:\/\/doi.org\/10.1183\/13993003.00537-2018","DOI":"10.1183\/13993003.00537-2018"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.        Motta I, Cozzi SN, Pontali E. QT prolongation for old and new drugs: how much should we really worry?. Int J Tuberc Lung Dis. 2022;26(4):298-301. https:\/\/doi.org\/10.5588\/ijtld.22.0072","DOI":"10.5588\/ijtld.22.0072"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.        Veerman K, Goosen J, Spijkers K, Jager N, Heesterbeek P, Telgt D. Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects. J Antimicrob Chemother. 2023;78(11):2660-2666. https:\/\/doi.org\/10.1093\/jac\/dkad276","DOI":"10.1093\/jac\/dkad276"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.        Hasan T, Medcalf E, Nyang\u2019wa BT, Egizi E, Berry C, Dodd M, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Clin Infect Dis. 2024;78(3):730-741. https:\/\/doi.org\/10.1093\/cid\/ciad653","DOI":"10.1093\/cid\/ciad653"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.        Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146-1154. https:\/\/doi.org\/10.1093\/jac\/dkac019","DOI":"10.1093\/jac\/dkac019"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.        Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38(3):253-269. https:\/\/doi.org\/10.1007\/s40264-015-0267-y","DOI":"10.1007\/s40264-015-0267-y"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.        Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117-128. https:\/\/doi.org\/10.1016\/S2213-2600(23)00389-2","DOI":"10.57740\/v9ye-0032"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.        Yao G, Zhu M, Nie Q, Chen N, Tu S, Zhou Y, et al. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis. J Int Med Res. 2023;51(1):3000605221148416. https:\/\/doi.org\/10.1177\/03000605221148416","DOI":"10.1177\/03000605221148416"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.        Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331-2343. https:\/\/doi.org\/10.1056\/NEJMoa2117166","DOI":"10.1056\/nejmoa2117166"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.        Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. [published correction appears in Lancet. 2022 Nov 19;400(10365):1766. doi: 10.1016\/S0140-6736(22)02307-8]. Lancet. 2022;400(10366):1858-1868. https:\/\/doi.org\/10.1016\/S0140-6736(22)02078-5","DOI":"10.3410\/f.742404740.793596980"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.        Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. https:\/\/doi.org\/10.1056\/NEJMoa1901814","DOI":"10.1056\/NEJMoa1901814"},{"key":"ref41","unstructured":"42.        Qiujing F, Weiwei W. Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis. Pak J Pharm Sci. 2020;33(3(Special)):1361-1366. PMID: 33361023."},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.        Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, et al. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis. 2020;71(4):1047-1054. https:\/\/doi.org\/10.1093\/cid\/ciz915","DOI":"10.1093\/cid\/ciz915"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.        Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25(2):190-195. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.012","DOI":"10.1016\/j.cmi.2018.07.012"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.        Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201-1213. https:\/\/doi.org\/10.1056\/NEJMoa1811867","DOI":"10.1056\/nejmoa1811867"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.        Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al., Efficacy, safety and toler-ability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161-70. https:\/\/doi.org\/10.1183\/09031936.00035114","DOI":"10.1183\/09031936.00035114"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:46:25Z","timestamp":1738788385000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4069\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":46,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240391","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}